Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Alosetron. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A known ✓ | P46098 | 3/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 4/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 3/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | HTR2B | P41595 | 2/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 1/20 | 1.00 |
| ▸ | HTR2A | P28223 | 1/20 | 1.00 |
| ▸ | HTR2C | P28335 | 1/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | CASP6 | P55212 | 1/20 | 0.98 |
| ▸ | CD44 | P16070 | 1/20 | 0.43 |
| ▸ | HTR3E | A5X5Y0 | 2/20 | 0.41 |
| ▸ | HTR3B | O95264 | 2/20 | 0.41 |
| ▸ | HTR3D | Q70Z44 | 2/20 | 0.41 |
| ▸ | HTR3C | Q8WXA8 | 2/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.40 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.40 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.40 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Alosetron SCHEMBL631 | 1.00 | KCNH2 (1.00) | KCNH2HTR3ACYP3A4CYP1A2HTR2B | |
| Alosetron SCHEMBL29387635 | 0.99 | CASP6 (1.00) | KCNH2HTR3ACYP3A4CYP1A2HTR2B | |
| Alosetron SCHEMBL806 | 0.99 | CASP6 (1.00) | KCNH2HTR3ACYP3A4CYP1A2HTR2B | |
| Alosetron SCHEMBL635233 | 0.98 | KCNH2 (0.96) | KCNH2HTR3ACYP3A4CYP1A2HTR2B | |
| Alosetron SCHEMBL850 | 0.95 | KCNH2 (0.90) | KCNH2HTR3ACYP3A4CYP1A2HTR2B | |
| SCHEMBL837 | 0.94 | KCNH2 (0.88) | KCNH2HTR3ACYP3A4CYP1A2HTR2B | |
| Alosetron SCHEMBL13345838 | 0.93 | KCNH2 (0.86) | KCNH2HTR3ACYP3A4CYP1A2HTR2B | |
| Alosetron SCHEMBL1046 | 0.92 | KCNH2 (0.85) | KCNH2HTR3ACYP3A4CYP1A2HTR2B | |
| Alosetron SCHEMBL1045 | 0.92 | KCNH2 (0.85) | KCNH2HTR3ACYP3A4CYP1A2HTR2B | |
| Alosetron SCHEMBL13345845 | 0.90 | KCNH2 (0.81) | KCNH2HTR3ACYP3A4CYP1A2HTR2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250197387-A1 | BCL-XL DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-06-19 | — | — | US | disclosed |
| US-20250179130-A1 | METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS | ON TARGET THERAPEUTICS LLC | 2025-06-05 | — | — | US | disclosed |
| US-20250059221-A1 | STAT DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2025-02-20 | — | — | US | disclosed |
| CN-118922420-A | TYK2 inhibitor synthesis and intermediate thereof | 武田药品工业株式会社 | 2024-11-08 | — | — | CN | disclosed |
| US-12060397-B2 | Soluble lipidated ligand agents for treating eye inflammation | TUFTS MEDICAL CENTER (US) | 2024-08-13 | — | — | US | disclosed |
| CN-115337288-A | Compositions comprising fibers formed from beta-1-4-glucan | 陈昭诚 | 2022-11-15 | — | — | CN | disclosed |
| CN-115087665-A | Engineered platelets for targeted delivery of therapeutic agents | JPV01有限公司 | 2022-09-20 | — | — | CN | disclosed |
| CN-217339582-U | Point-of-care drug delivery device | 建南德克公司 | 2022-09-02 | — | — | CN | disclosed |
| CN-111388474-B | Application of milbexate in preparation of medicine for preventing and/or treating radiation injury | 中国人民解放军军事科学院军事医学研究院 | 2022-08-02 | — | — | CN | disclosed |
| CN-114732899-A | Dosing regimens for MAdCAM antagonists | 辉瑞公司 | 2022-07-12 | — | — | CN | disclosed |
| US-20220135633-A1 | METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS | ON TARGET THERAPEUTICS LLC | 2022-05-05 | — | — | US | disclosed |
| CN-114377125-A | Dosing regimens for MAdCAM antagonists | 辉瑞公司 | 2022-04-22 | — | — | CN | disclosed |
| CN-114028387-B | Application of Brusatol in preparation of anti-radiation injury medicine | 中国人民解放军军事科学院军事医学研究院 | 2022-04-08 | — | — | CN | disclosed |
| CN-114028387-A | Application of Brusatol in preparation of anti-radiation injury medicine | 中国人民解放军军事科学院军事医学研究院 | 2022-02-11 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220135633-A1 | METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS | LDLR, HDLBP, LIPG | HTR3A 2833/4885KCNH2 4836/4885CYP3A4 2859/4885 |
| US-20250059221-A1 | STAT DEGRADERS AND USES THEREOF | STAT4, STAT1, STAT3 | HTR3A 3388/4885KCNH2 4870/4885CYP3A4 143/4885 |
| US-20250197387-A1 | BCL-XL DEGRADERS AND USES THEREOF | XIAP, BCL2L1, BCL2L10 | HTR3A 4307/4885KCNH2 4626/4885CYP3A4 4407/4885 |
| US-20250179130-A1 | METHODS AND SYSTEMS FOR DESIGNING AND/OR CHARACTERIZING SOLUBLE LIPIDATED LIGAND AGENTS | LDLR, HDLBP, LIPG | HTR3A 2833/4885KCNH2 4836/4885CYP3A4 2859/4885 |
| US-12060397-B2 | Soluble lipidated ligand agents for treating eye inflammation | LIPG, CD40, LDLR | HTR3A 3350/4885KCNH2 4689/4885CYP3A4 2606/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.